Profilo
F.
Andrew Dorr served as the Chief Medical Officer at Ionis Pharmaceuticals, Inc. from 1996 to 2003.
He then worked as the Chief Operating Officer at Salmedix, Inc. in 2004.
Later, he became the Chief Medical Officer at Spyre Therapeutics, Inc. Dr. Dorr received his undergraduate degree from Davidson College and his doctorate from The University of North Carolina at Charlotte.
Precedenti posizioni note di F. Andrew Dorr
| Società | Posizione | Fine |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 21/04/2017 |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Direttore operativo | 01/08/2004 |
| IONIS PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2003 |
Formazione di F. Andrew Dorr
| Davidson College | Undergraduate Degree |
| The University of North Carolina at Charlotte | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Salmedix, Inc.
Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- F. Andrew Dorr
